Pfizer refused to provide safety data and studies India required for its COVID-19 shot. The Indian government announced its committee does not recommend the injection for emergency use.
India’s death rate for COVID-19 is 1.3 percent. With 1.3 billion people, the health department demanded a double-blind study on the shot’s effectiveness and safety.
The country’s health committee “noted that incidents of palsy, anaphylaxis and other serious adverse events have been reported…Further, the firm (Pfizer) has not proposed any plan to generate safety and immunogenicity data in the Indian population.”
Two days after the government announced it was not recommended, Pfizer proclaimed it was “withdrawing” its request for emergency use in India.
Liberty Counsel chairman Mat Staver wrote that updates on the CDC’s vaccine reporting system show injections have been linked to miscarriages, Bell’s palsy and death.
“And the number of people worldwide who died shortly after the injection is climbing,” Staver wrote. “India had good reason to demand safety data because such information is standard operating procedures for any new medication. Vaccines take between 7-10 years to get approval, five years of which is devoted to testing.”
The Pfizer shot isn’t actually a vaccine, Staver wrote. It is a novel mRNA application using genetic materials. And it had just a few months of testing.
Staver wrote that in Israel, at least 4,500 people contracted COVID after their first Pfizer shot. Of those, 375 were hospitalized.
